Sequential treatment of growth hormone pituitary adenoma invading cavemous sinus with short-term and long-term octreotide and bromocriptine

FU Jingyun; HUANG Shiying; HUANG Shenting; YAN Qianyu; XU Zhao; HU Yudi

doi:10.3969/j.issn.1002-266X.2017.11.002

Abstract：Objective To observe the efficacy of short-term, long-term octreotide and bromocriptine in the sequential treatment of growth hormone pituitary adenoma invading the cavernous sinus.Methods Sixteen patients with growth hormone pituitary adenoma invading the cavernous sinus were randomly divided into two groups, 8 in each.Patients in the observation group were given subcutaneous injection of short-term octreotide 100 μg each time, 3 times/d for 1 week.Then, the long-term octreotide was deep injected into the buttock muscle, 20 mg each time, once every 28 days, for 3 times, followed by oral sniffing 7.5mg/d, for 3 months.The patients in the control group were deep injected with long-term octreotide, 20 mg each time, once every 28 days, for 6 months.The clinical symptom scores, serum GH valleys, serum IGF-1 and tumor volume before and after treatment were observed and compared between these two groups.Statistics on gastrointestinal adverse reactions and total treatment costs between the two groups was conducted.Results No significant difference was found in the clinical symptoms score, serum GH valleys, serum IGF-1, tumor volume between the two groups before and after treatment (all P>0.05).The incidence of gastrointestinal adverse reactions in the observation (2 cases) was lower than that (5 cases) in the control group (25% vs 62.5%), P<0.05.The total cost of the observation group was (33 000±2 000) yuan, which was lower than that of the control group [(55 000±9 000) yuan], P<0.05.Conclusions The efficacy of short-term, long-term octreotide and bromocriptine in the sequential treatment of growth hormone pituitary adenoma invading the cavernous sinus is the same as the only use of long-term octreotide, but short-term, long-term octreotide and bromocriptine can decrease the gastrointestinal adverse reaction and total cost of the treatment.